- Home
- PFE vs NVS Comparison
PFE vs NVS Comparison
Compare PFE & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PFE | NVS |
|---|---|---|
| Founded | 1849 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.6B | 266.5B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | PFE | NVS |
|---|---|---|
| Price | $25.66 | $144.55 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 5 |
| Target Price | $27.18 | ★ $118.00 |
| AVG Volume (30 Days) | ★ 43.8M | 1.4M |
| Earning Date | 02-03-2026 | 02-04-2026 |
| Dividend Yield | ★ 6.64% | 1.81% |
| EPS Growth | ★ 131.89 | N/A |
| EPS | 1.73 | ★ 7.30 |
| Revenue | ★ $62,785,000,000.00 | $56,372,000,000.00 |
| Revenue This Year | N/A | $9.38 |
| Revenue Next Year | N/A | $2.69 |
| P/E Ratio | ★ $15.00 | $19.61 |
| Revenue Growth | 3.89 | ★ 12.88 |
| 52 Week Low | $20.92 | $97.39 |
| 52 Week High | $27.69 | $146.35 |
Technical Indicators
Market Signals| Indicator | PFE | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 67.50 |
| Support Level | $24.97 | $142.26 |
| Resistance Level | $25.77 | $146.35 |
| Average True Range (ATR) | 0.44 | 1.94 |
| MACD | 0.06 | 0.19 |
| Stochastic Oscillator | 71.91 | 82.72 |
Price Performance
Historical ComparisonAbout PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.